Role of hydrogen sulfide in hepatic ischemia‐reperfusion–induced injury in rats

Kai Kang, Mingyan Zhao, Hongchi Jiang, Gang Tan, Shangha Pan, Xueying Sun – 29 September 2009 – Hydrogen sulfide (H2S) displays anti‐inflammatory and cytoprotective activities as evidenced by the inhibition of myocardial ischemia‐reperfusion injury and production of lipid peroxidation. H2S also exerts many physiological or pathological effects on livers.

Survival after orthotopic liver transplantation: The impact of antibody against hepatitis B core antigen in the donor

Lei Yu, Thomas Koepsell, Lisa Manhart, George Ioannou – 29 September 2009 – Liver transplantation using grafts from donors with antibody against hepatitis B core antigen (anti‐HBc) increases the recipients' risk of developing hepatitis B virus (HBV) infection post‐transplantation. Our aim was to assess whether using such grafts was associated with reduced posttransplantation survival and whether this association depended on recipients' prior exposure to HBV on the basis of their pretransplantation serological patterns.

Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation

Luis Olmedilla, José María Pérez‐Peña, Cristina Ripoll, Ignacio Garutti, Roberto de Diego, Magdalena Salcedo, Consuelo Jiménez, Rafael Bañares – 29 September 2009 – Early diagnosis of graft dysfunction in liver transplantation is essential for taking appropriate action. Indocyanine green clearance is closely related to liver function and can be measured noninvasively by spectrophotometry.

Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial

Paolo De Simone, Herold J. Metselaar, Lutz Fischer, Jérôme Dumortier, Karim Boudjema, Jean Hardwigsen, Lionel Rostaing, Luciano De Carlis, Faouzi Saliba, Frederik Nevens – 29 September 2009 – Calcineurin inhibitors (CNIs) contribute to renal dysfunction following liver transplantation. This prospective, randomized, multicenter, 6‐month study (with an additional 6 months of follow‐up) evaluated whether everolimus with CNI reduction or discontinuation would improve renal function in maintenance liver transplant recipients experiencing CNI‐related renal impairment.

Risk factors for recurrence of autoimmune hepatitis after liver transplantation

Aldo J. Montano‐Loza, Andrew L. Mason, Mang Ma, Ravin J. Bastiampillai, Vincent G. Bain, Puneeta Tandon – 29 September 2009 – Autoimmune hepatitis has been reported to recur after liver transplantation. The aim of our study was to evaluate the risk factors associated with recurrence of autoimmune hepatitis. Forty‐six patients that underwent liver transplantation because of end‐stage liver disease secondary to autoimmune hepatitis were studied. Recurrence of autoimmune hepatitis was diagnosed in 11 of the 46 (24%) patients, and the overall 5‐year probability of recurrence was 18%.

Conivaptan increases serum sodium in hyponatremic patients with end‐stage liver disease

Jacqueline G. O'Leary, Gary L. Davis – 29 September 2009 – Hyponatremia is associated with increased mortality in patients with end‐stage liver disease and a greater risk of perioperative mortality with liver transplantation. We performed a retrospective review of our experience with conivaptan as a means of acutely increasing serum sodium in end‐stage liver disease patients. The primary group consisted of 15 patients with end‐stage liver disease who remained hyponatremic despite discontinuation of diuretics and a 1‐L fluid restriction.

Subscribe to